Search hospitals > Michigan > Farmington
Weisberg Cancer Treatment Center
Claim this profileFarmington, Michigan 48334
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Pancreatic Cancer
Conducts research for Breast cancer
Conducts research for Cancer
185 reported clinical trials
27 medical researchers
Summary
Weisberg Cancer Treatment Center is a medical facility located in Farmington, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Pancreatic Cancer, Breast cancer, Cancer and other specialties. Weisberg Cancer Treatment Center is involved with conducting 185 clinical trials across 256 conditions. There are 27 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Hirva Mamdani, MD, and Dipenkumar Modi, M.D..Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute3 years of reported clinical research
Expert in Squamous Cell Carcinoma
Studies Head and Neck Cancers
29 reported clinical trials
45 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute6 years of reported clinical research
Studies Pancreatic Cancer
Studies Solid Tumors
22 reported clinical trials
65 drugs studied
Hirva Mamdani, MDKarmanos Cancer Institute5 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
29 drugs studied
Dipenkumar Modi, M.D.Karmanos Cancer Institute3 years of reported clinical research
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
22 reported clinical trials
48 drugs studied
Clinical Trials running at Weisberg Cancer Treatment Center
Lung Cancer
Laryngeal Cancer
Throat Cancer
Bladder Cancer
Esophageal cancer
Oropharyngeal Carcinoma
Breast Cancer
Lip and Oral Cavity Cancer
Squamous Cell Carcinoma
Oral Cancers
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Weisberg Cancer Treatment Center?
Weisberg Cancer Treatment Center is a medical facility located in Farmington, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Pancreatic Cancer, Breast cancer, Cancer and other specialties. Weisberg Cancer Treatment Center is involved with conducting 185 clinical trials across 256 conditions. There are 27 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Hirva Mamdani, MD, and Dipenkumar Modi, M.D..
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.